A new study of adults with systemic lupus erythematosus (SLE) found those with mental health diagnoses (depression, anxiety, and posttraumatic stress disorder (PTSD)) have much higher repeat emergency ...
A new pooled analysis of adults with systemic lupus erythematosus (SLE) found commonly used patient-reported measures varied meaningfully in sensitivity to clinical changes in SLE, disease course and ...
A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and ...
Novartis and Bristol Myers Squibb have paused their clinical trials studying their respective CAR-T cell therapies for lupus and other autoimmune diseases while they review safety findings. Novartis ...
The Lancet has published the positive full results ofUCB and Biogen’s Phase III PHOENYCS GO study of dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, for people with ...
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® (obinutuzumab) for adults with systemic lupus erythematosus (SLE). The ...
Join us for this webinar to learn how lupus can affect the central nervous system (CNS), including neuropsychiatric lupus (NPSLE) and gain a better understanding of common NPSLE symptoms. We’ll also ...
Save the Date for the 2027 National Lupus Advocacy Summit! Join us April 4-6, 2027 in Washington, DC for the nation's largest lupus advocacy event of the year! The Lupus Foundation of America's ...
The U.S. Food and Drug Administration (FDA) has granted Johnson & Johnson’s, nipocalimab, Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). This ...
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results